XML 27 R14.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments (Tables)
3 Months Ended
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Schedule of exercisable share purchase warrants outstanding
            
   Number of Shares 

Weighted

Average

Exercise Price

($)

 Balance, September 30, 2019    350,000    4.19 
 Granted    150,000    3.17 
 Balance, September 30, 2020 and December 31, 2020    500,000    3.88 
 

Granted 

         
 Balance, September 30, 2020 And December 31, 2020         
Schedule of share purchase warrants outstanding
          
Number  Exercise Price  Expiry Date
 350,000    $4.19   June 30, 2021
 150,000    $3.17   May 6, 2024
 500,000         
Schedule of outstanding stock purchase options
                   
   Number of Shares  Weighted Average Exercise Price ($)  Weighted
Average
Grant Date
Fair Value ($)
  Aggregate
intrinsic
value ($)
Outstanding, September 30, 2019    8,462,933    3.58        4,115,032
Granted    1,695,000    2.96    2.27 
Forfeited    (68,332)   3.01      
Exercised    (13,335   3.15      
Outstanding, September 30, 2020    10,076,266    3.48        14,982,581
Granted    1,225,000    5.49    4.16 
Outstanding, December 31, 2020    11,301,266    3.69        21,622,986
Exercisable, December 31, 2020    7,540,018    3.64        15,482,966
Schedule of general and administrative expenses and research and development expenses
          
   2020  2019
General and administrative  $422,823   $481,101 
Research and development   516,491    783,323 
Total share based compensation  $939,314   $1,264,424 
Schedule of weighted average assumptions for fair value of each option award
          
   2020  2019
Risk-free interest rate   0.62%   1.88%
Expected life of options (years)   5.59    5.21 
Annualized volatility   96.16%   101.60%
Dividend rate   0.00%   0.00%